Bank of America
AQST icon

Bank of America’s Aquestive Therapeutics AQST Stock Holding History

Bank of America’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.98M Buy
2,405,050
+1,197,459
+99% +$4.86M ﹤0.01% 2962
2025
Q4 		$7.8M Sell
1,207,591
-14,544
-1% -$90.6K ﹤0.01% 3032
2025
Q3 		$6.83M Sell
1,222,135
-61,005
-5% -$264K ﹤0.01% 3704
2025
Q2 		$4.25M Sell
1,283,140
-47,385
-4% -$136K ﹤0.01% 4067
2025
Q1 		$3.86M Buy
1,330,525
+640,241
+93% +$1.94M ﹤0.01% 4078
2024
Q4 		$2.46M Buy
690,284
+621,614
+905% +$2.87M ﹤0.01% 4264
2024
Q3 		$342K Sell
68,670
-161,484
-70% -$628K ﹤0.01% 5724
2024
Q2 		$598K Buy
230,154
+207,561
+919% +$693K ﹤0.01% 5234
2024
Q1 		$96.2K Buy
22,593
+13,881
+159% +$46.2K ﹤0.01% 6260
2023
Q4 		$17.6K Buy
+8,712
New +$15.4K ﹤0.01% 6809
2023
Q1 		– Sell
-102
Closed -$92 – 7783
2022
Q4 		$92 Sell
102
-482
-83% -$453 ﹤0.01% 7684
2022
Q3 		$0 Sell
584
-128
-18% -$145 ﹤0.01% 7807
2022
Q2 		$0 Sell
712
-3,870
-84% -$5.15K ﹤0.01% 7989
2022
Q1 		$12K Sell
4,582
-31,789
-87% -$92.8K ﹤0.01% 7678
2021
Q4 		$141K Buy
36,371
+28,814
+381% +$145K ﹤0.01% 6696
2021
Q3 		$33K Sell
7,557
-21,171
-74% -$83K ﹤0.01% 7219
2021
Q2 		$114K Sell
28,728
-9,151
-24% -$36.5K ﹤0.01% 6442
2021
Q1 		$197K Buy
37,879
+15,534
+70% +$82.6K ﹤0.01% 6050
2020
Q4 		$119K Sell
22,345
-18,406
-45% -$110K ﹤0.01% 5893
2020
Q3 		$198K Sell
40,751
-9,799
-19% -$64K ﹤0.01% 5304
2020
Q2 		$245K Buy
50,550
+24,644
+95% +$113K ﹤0.01% 5099
2020
Q1 		$57K Sell
25,906
-337
-1% -$1.28K ﹤0.01% 5812
2019
Q4 		$153K Buy
+26,243
New +$137K ﹤0.01% 5782
2019
Q3 		– Sell
-13,307
Closed -$56K – 7239
2019
Q2 		$56K Buy
13,307
+8,934
+204% +$45.7K ﹤0.01% 6259
2019
Q1 		$30K Sell
4,373
-3,660
-46% -$25.6K ﹤0.01% 6379
2018
Q4 		$50K Buy
8,033
+7,541
+1,533% +$95.2K ﹤0.01% 6214
2018
Q3 		$9K Buy
+492
New +$8.11K ﹤0.01% 6694

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Bank of America's AQST Position: Q1 2026 in Review

Bank of America increased its Aquestive Therapeutics (AQST) stake by 99% in Q1 2026, buying an estimated $4.86M and bringing the position to 2,405,050 shares worth $9.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2962.

Bank of America first reported a position in AQST in Q3 2018 and has held it in 27 quarters since. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Bank of America held 2,405,050 shares of Aquestive Therapeutics worth $9.98M as of Q1 2026.
  • Bank of America bought 1,197,459 Aquestive Therapeutics shares in Q1 2026, an estimated $4.86M.
  • Aquestive Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2962 holding.
  • Bank of America first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.